Enovis (NYSE:ENOV) Downgraded to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of Enovis (NYSE:ENOV) from a buy rating to a hold rating in a research note released on Sunday morning.

Other equities analysts have also recently issued reports about the company. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. Wells Fargo & Company raised shares of Enovis to a “strong-buy” rating in a research report on Wednesday, March 18th. UBS Group restated a “buy” rating and issued a $50.00 target price on shares of Enovis in a research note on Monday, January 5th. Evercore reiterated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Finally, BTIG Research raised their price objective on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Buy” and a consensus price target of $47.43.

Enovis Trading Down 3.7%

NYSE:ENOV opened at $21.74 on Friday. Enovis has a 52 week low of $21.00 and a 52 week high of $40.69. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The firm’s fifty day moving average is $23.26 and its 200-day moving average is $27.49. The firm has a market cap of $1.24 billion, a P/E ratio of -1.05 and a beta of 1.46.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. Enovis’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts expect that Enovis will post 2.79 earnings per share for the current year.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 1,000 shares of the firm’s stock in a transaction on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the purchase, the insider owned 43,640 shares in the company, valued at approximately $1,112,820. This represents a 2.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have bought 5,000 shares of company stock valued at $121,983. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Enovis

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC increased its stake in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after purchasing an additional 73,116 shares during the period. Empowered Funds LLC grew its holdings in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after purchasing an additional 749 shares during the period. PNC Financial Services Group Inc. increased its position in Enovis by 7.4% in the second quarter. PNC Financial Services Group Inc. now owns 9,490 shares of the company’s stock worth $298,000 after buying an additional 650 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Enovis by 43.8% in the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after buying an additional 408,608 shares during the period. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.